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ABSTRACT
Introduction: Insulinomas are rare pancreatic neuroendocrine tumors derived from beta cells 
responsible for insulin secretion. These tumors are typically manifested by hypoglycemia signs 
and symptoms, which might be non-specific leading to a delay in the diagnosis. The present study 
describes the experience in the approach of patients with insulinoma at Fundación Valle del Lili, Cali, 
Colombia. Case Presentation: A retrospective search of patients with the diagnosis of insulinoma 
within the database of the pathology service was performed between March 2002 and February 2017. 
Parameters such as the lesion size and localization, the immunohistochemistry findings, the serum 
levels of glucose, the insulin and C-peptide levels, the presence of metastasis, and the development 
of diabetes after surgery were evaluated. A total of nine patients with a diagnosis of insulinoma 
were enrolled in the study. The cohort comprised of seven men and two women, aged 30–50 years. 
Whipple triad was present in seven patients. The most common symptom was hypoglycemia-related 
syncope. All patients underwent surgical resection of the tumor with subsequent resolution of the 
symptoms. Only one patient was diagnosed with diabetes in the postoperative period. Conclusion: 
In the last 15 years, only nine cases of insulinoma were detected at the Fundación Valle del Lili, 
which is consistent with the low incidence of the disease. A higher frequency of the disease is noted 
in men, unlike that in the literature. However, other clinical and pathological features from large 
studies are in agreement with the current data. Nevertheless, continual experience in the management 
and identification of these cases is essential as common clinical manifestations may not be observed.
INTRODUCTION
Insulinomas are rare neuroendocrine tumors derived from in-
sulin-producing beta pancreatic cells (1) with an annual inci-
dence of four cases per million individuals (2). The principal-
ly affected individuals are between 41 and 50-years-old (3), 
of which, 57% are women. A majority of these tumors (90%) 
are benign (2,4). Up to 6% of the cases are related to the ge-
netic syndrome known as multiple neuroendocrine neoplasia 
type 1 (MEN-1) (5,6). The clinical manifestations of insuli-
nomas are those typical of hyperinsulinemic hypoglycemia 
(4). Thus, the initial identification of the Whipple triad is es-
sential. It consists of neuroglycopenic symptoms secondary 
to low blood glucose levels that are promptly relieved after 
glucose administration (7-9). Occasionally, the symptom-
atology could be non-specific leading to a delayed diagnosis. 
Herein, we describe our experience with the diagnosis and 
treatment of insulinomas at Fundacion Valle del Lili (Cali, 
Colombia) depicting the demographic characteristics and 
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clinical course and comparing it with the available literature 
in order to identify the putative patterns in the local popula-
tion.
CASE PRESENTATION
A retrospective search of the database of the pathology ser-
vice at Fundacion Valle del Lili was conducted, and cases 
of patients diagnosed with insulinoma between March 2002 
and February 2017 were retrieved. The variables assessed 
included sociodemographic information, symptoms, gly-
cemia, serum C-peptide levels, insulinemia, tumor charac-
teristics, metastasis, and the onset of diabetes after surgical 
resection.
Continuous variables were expressed as median and in-
terquartile range (IQR) or as mean and standard deviation 
(SD). Categorical variables were expressed as frequencies 
and percentages. All statistical descriptions were performed 
using STATA 12.
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The report of these case series was approved and 
supervised by the Ethics Committee on Biomedical Re-
search of Fundacion Valle del Lili.
A total of nine patients, diagnosed with insulinoma were 
included in this study. The cohort comprised of seven (77%) 
men and two (22%) women, and 44.4% of the group was be-
tween 30 and 50-years-old. The median time-lapse between 
the initial appearance of symptoms of hypoglycemia and 
the surgical intervention was 8 (range, 3–60) months. The 
most frequent signs and symptoms were fasting hypogly-
cemia (100%), Whipple triad (77%), and hypoglycemia-re-
lated syncope (66%). All diagnosis were confirmed by the 
72-hour-fast test. The mean glycemia was 43.3 mg/dL. In 
addition, the serum C-peptide level was measured in only 
six patients, and the median level was found to be 5.4 ng/mL, 
while the mean insulinemia was 32.84 µIU/mL. All patients 
underwent surgical resection of the tumor that was common-
ly localized in the tail of the pancreas in 33% of the cases, 
followed by body and head localization in the pancreas. None 
of the tumors were metastatic or malignant. Furthermore, 
different staining techniques were used for the immunohis-
tochemistry of the resected specimens. Consequently, the 
staining for synaptophysin was positive in all the 6 samples, 
staining for insulin was positive in 3/4 samples, and staining 
for chromogranin was positive in all 5 samples. Only one pa-
tient was diagnosed with diabetes mellitus postoperatively, 
and although it was new onset, the medical record revealed 
insulin-dependent type 2 diabetes mellitus before the diag-
nosis of insulinoma, which in turn, favored persistent hypo-
glycemia (Table 1).
Peptide C levels were reported in only six patients from 
the cohort included in the study.
DISCUSSION
In the last 15 years, only nine cases of insulinoma were de-
tected at Fundacion Valle del Lili, which is consistent with 
the low incidence of the disease. Male patients comprised 
77% of the cohort in contrast to other studies that reported 
female predominance, which accounted for up to 57% of the 
cases (3,7). Additionally, the most frequent age of onset was 
30–50 years (44%), coinciding with data from large cohort 
studies that reported a mean onset age of 47 years (2-3).
Documenting the classic Whipple triad is a key diagnos-
tic approach to hypoglycemia (10). Insulinomas are one of 
the most frequent causes of this manifestation after factitious 
hypoglycemia is excluded (11). Herein, this manifestation 
was detected in 77% of the patients. Furthermore, insuli-
noma-related hypoglycemia is typically described as fast-
ing hypoglycemia. However, the clinical presentation has 
evolved, and up to 6% of the cases might present only post-
prandial hypoglycemia, while 21% exhibited a combination 
of fasting and postprandial hypoglycemia (7).
 
A majority of these tumors are benign (90%) and are pre-
sented as single lesions (87%), <2 cm, with homogeneous 
localization in the head, body, or tail of the pancreas (2,4,14). 
In the current case series, a significant proportion of tumors 
was >2 cm (33%) with a slight predominance of localization 
in the tail of the pancreas (33%). Herein, no malignant pro-
cesses were found, which might be attributed to the small 
number of cases retrieved from our database.
The surgical resection of the tumor is considered as the 
treatment of choice due to a 95% efficacy in the resolution 
of the symptoms (4). All patients underwent successful 
surgical removal of the tumor, with no relapse during the 
follow-up, indicating a satisfactory prognosis. Therefore, 
pharmacological alternatives such as diazoxide, everolimus, 
and octreotide were not necessary for the treatment of the 
tumor (4,10,15-18).
The coexistence of diabetes mellitus with insulinoma has 
been rarely reported in the literature. The casuistry of the 
Mayo Clinic consisting of 313 patients presented only one 
Table 1. Demographic and clinical characteristics of 
patients with insulinoma
Variable Patients (n=9)
Age, Median (IQR) 40 (27.5–63)
Gender, n (%)
Male 7 (77)
Female 2 (22)
Time-lapse between diagnosis 
and surgical removal (months), 
Median (IQR)
8 (6–12)
Hypoglycemic symptoms, n (%)
Syncopes 6 (66)
Paresthesias 4 (44)
Seizures 4 (44)
Glycemia (mg/dL), Mean (SD) 43.3 (22.44)
Serum C peptide (ng/mL), 
Median (IQR)
5.4 (2.0–5.7) 
Insulinemia (µUI/mL), Mean (SD) 32.8 (21.5) 
Localization of the tumor, n (%)
Tail 3 (33)
Body 2 (22)
Head 2 (22)
Neck 1 (11)
Uncinate process 1 (11)
Diameter of the lesion, n (%)
<2 cm 6 (66)
>2 cm 3 (33)
Ki-67 cellular proliferation index n (%)
<2 3 (33)
2–20 3 (33)
>20 0 (0)
No report 3 (33)
IQR: Interquartile range, SD: Standard deviation
 The final diagnosis was established by unusually high 
insulinemia associated with hypoglycemia that was further 
confirmed by a 72-hour fasting test (12,13). The mean plas- 
ma insulin level in our patients was 32.84 !IU/mL,  exceed- 
ing the 5 !IU/mL  insulin threshold established for diagno- 
sis(5,12).
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patient with both diseases. In the current study, one case was 
reported to be persisting with diabetes mellitus after tumor 
resection.
In conclusion, insulinoma is rare and should be suspected 
in unusual situations; for example, as a differential diagnosis 
of hypoglycemia in the diabetic patient, since this disease 
can lead to fatal outcomes. In the current study, we identified 
cases with general characteristics that match with the data 
from large studies. Nevertheless, common clinical manifes-
tations may not be detected frequently, and hence, continual 
experience is essential with respect to the management and 
identification of these cases.
STUDY LIMITATIONS
The pathology service database from Fundación Valle del 
Lili, Cali, Colombia was reviewed. Only nine cases of insu-
linoma were reported in the last 15 years. This small number 
of cases was a limitation of the current study.
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